ENGOT-ov89/GEICO144-O/DESTINY-OVARIAN-01: “A Phase 3, Open-label, Multicenter, Randomized Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First- line Maintenance Therapy in HER2-Expressing Ovarian Cancer”.